# Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

> **NCT07426484** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 80 (estimated)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma
- Skin Cancer

## Interventions

- **DRUG:** Cosibelimab
- **DRUG:** Prednisone
- **DRUG:** Sirolimus
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT07426484
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2030-12-15
- **Final completion:** 2032-12-15
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07426484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07426484, "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07426484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*